The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.
The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.
No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.
The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.
Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.
The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV, a significant step toward making the drug available inexpensively and more quickly in low-income countries.
An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.
The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.
Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.
The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.
The FDA has approved Bristol Myers Squibb's Camzyos (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients, making it the first cardiac myosin inhibitor approved for children with this painful heart condition. The approval is based on positive results from the Phase 3 SCOUT-HCM trial.
The FDA has expanded the indication for baricitinib (Olumiant), a once-daily oral JAK inhibitor, to include adolescents aged 12 and older with severe alopecia areata. This marks the second JAK inhibitor treatment approved for adolescents with the condition.
The FDA has approved Roche's obinutuzumab (Gazyva), an anti-CD20 agent, for treating idiopathic nephrotic syndrome in patients as young as 2 years old. This marks the first new drug approval for this kidney condition in seven decades.
The FDA has approved Juvmo (tavapadon), the first and only dopamine agonist designed to selectively target D1/D5 receptors for treating adults with Parkinson's disease. The once-daily oral tablet can be taken with or without levodopa therapy and came from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics.
The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib), a once-daily pill for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes soft tissue to turn to bone. This marks the third FDA-approved treatment for FOP, following recent approvals of Regeneron's Pasatru and Ipsen's Sohonos.
The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.
Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.
The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.
The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.
The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.
The FDA has approved Curium's Bexlutry (lutetium Lu 177 dotatate injection), marking the industry's first radioligand equivalent and setting up the first generic competition for Novartis in the radioligand therapy field. The approval came after a court cleared Curium of all patent claims.
The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.
The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) for breast cancer treatment, marking a rare divergence from its expert advisory panel's recommendation and opening a new ctDNA-guided treatment paradigm.
The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.
The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.
The FDA approved ustekinumab (Stelara) on August 28, 2026 for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older, making it the first non-TNF biologic approved for pediatric IBD.
Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.
The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.
The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.
Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.
Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.
The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.
The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.
The U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for treating neovascular age-related macular degeneration (wet AMD), marking the first FDA-approved ophthalmic formulation of bevacizumab after 20 years of off-label use. The approval comes on Outlook Therapeutics' fourth regulatory attempt, though the company faces cash constraints as it enters commercialization.
The U.S. Food and Drug Administration approved a nonprescription fixed-dose combination pill containing acetaminophen (650 mg) and naproxen sodium (220 mg), marketed as Tylenol with Naproxen by Kenvue. The medication provides up to 12 hours of pain relief for patients aged 12 and older.
The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.
The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.
The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.
The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.
The U.S. Food and Drug Administration has approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease, marking the first FDA-approved treatment for the condition and setting up direct competition with Amgen's blockbuster drug Tepezza.
The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.
The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.
The U.S. Food and Drug Administration on Tuesday approved bemotrizinol as a permitted active ingredient for over-the-counter sunscreens, marking the first new UV filter cleared since the late 1990s. The broad-spectrum ingredient has been widely used in Europe and Asia for years.
Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.
The FDA approved Ranluspec as the first interchangeable ranibizumab biosimilar, Biocon launched denosumab biosimilars Bosaya and Aukelso in the US, and Celltrion's Truxima became the first Korean biosimilar to lead its segment in US prescriptions.